TABLE 2.
Correlations between ASAP1 expression and clinicopathological characteristics in patients with HCC (n = 149).
| Variables | ASAP1 expression | p-value | |
|---|---|---|---|
| Low expression (%) (n = 60) | High expression (%) (n = 89) | ||
| Age | 0.550 | ||
| <60 years | 39 (38.6%) | 62 (61.4%) | |
| ≥60 years | 21 (51.4%) | 27 (48.6%) | |
| Sex | 0.018 | ||
| Female | 21 (56.8%) | 16 (43.2%) | |
| Male | 39 (34.8%) | 73 (65.2%) | |
| Underlying diseases | 0.054 | ||
| Non‐cirrhotic HCC | 11 (61.1%) | 7 (38.9%) | |
| Cirrhotic HCC | 49 (37.4%) | 82 (62.6%) | |
| AFP level a | 0.307 | ||
| <400 | 44 (45.4%) | 53 (54.6%) | |
| ≥400 | 12 (35.3%) | 22 (64.7%) | |
| Tumor size | 0.793 | ||
| ≤5 cm | 43 (41.0%) | 62 (59.0%) | |
| >5 cm | 17 (38.6%) | 27 (61.4%) | |
| Histological grade | 0.013 | ||
| Grade 1 or 2 | 34 (51.5%) | 32 (48.5%) | |
| Grade 3 or 4 | 26 (31.3%) | 57 (68.7%) | |
| Vessel invasion | 0.021 | ||
| Not identified | 43 (47.8%) | 47 (52.2%) | |
| Present | 17 (28.8%) | 42 (71.2%) | |
| Perineural invasion | 0.649 b | ||
| Not identified | 59 (40.7%) | 86 (59.3%) | |
| Present | 1 (25.0%) | 3 (75.0%) | |
| Tumor focality | 0.226 | ||
| Single | 53 (42.4%) | 72 (57.6%) | |
| Multiple | 7 (29.2%) | 17 (70.8%) | |
| Proliferation index (Ki-67 index) | 0.844 | ||
| <1% | 45 (39.5%) | 69 (60.5%) | |
| ≥1% | 15 (42.9%) | 20 (57.1%) | |
| Stage (AJCC 8th edition) | 0.020 b | ||
| I or II | 56 (44.4%) | 70 (55.6%) | |
| III | 4 (17.4%) | 19 (82.6%) | |
a
AFP level, 18 cases missed.
b
Fisher’s exact test.
Acronyms: HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; ASAP1, ArfGAP with SH3 domain ankyrin repeat and PH domain 1; AJCC, American Joint Committee on Cancer.